{
    "title": "GSK's long-acting injection beats Truvada in HIV prevention trial",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8330507/GSKs-long-acting-injection-beats-Truvada-HIV-prevention-trial.html",
    "date": "2020-05-18",
    "keywords": [
        "injection",
        "drug",
        "trial",
        "cabotegravir",
        "gsk",
        "infection",
        "truvada",
        "pill",
        "prevention",
        "market",
        "treatment",
        "burger",
        "care",
        "year",
        "research",
        "gilead",
        "hiv",
        "approval",
        "cabenuva",
        "glaxosmithkline",
        "month",
        "viiv",
        "unit",
        "foothold",
        "monitoring",
        "board",
        "standard",
        "drugmaker",
        "monday",
        "segment",
        "september",
        "patent",
        "part",
        "october",
        "toxic",
        "head",
        "longacting",
        "route",
        "administer",
        "routine",
        "risk",
        "clinic",
        "inbetween",
        "need",
        "equation",
        "adherence",
        "smith",
        "spokesman",
        "gmt",
        "gain",
        "stoxx",
        "health",
        "multibillion",
        "opportunity",
        "consensus",
        "nothing",
        "note",
        "canada",
        "combination",
        "company",
        "goahead",
        "readout",
        "pfizer",
        "shionogi",
        "co",
        "ltd",
        "division",
        "reporting",
        "louise"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}